The Centre said it is monitoring the supply of drugs such as Remdesivir, Ivermectin and Favipiravir, essential for treating moderate to critical Covid patients. The Centre said it had ramped up production of these drugs and imported them in large quantities to ensure uninterrupted supply.
A couple of days ago, the Indian government said it had received 530,000 Remdesivir vials as foreign aid from various countries such as the US and France, to help combat the second wave of the Covid-19 pandemic.
“The availability of these drugs is being monitored by implementing a three-pronged strategy of supply chain management, demand side management and affordability,” the Centre said in a statement.
The drugs whose supply is being monitored include those in ICMR's Covid treatment protocol, such as Remdesivir, Enoxaparin, Dexamethasone and Ivermectin, and non-protocol drugs such as Favipiravir, Amphotericin and Apixaban.
The Centre added that it will increase the production of Ivermectin, a Covid protocol drug, by five times, from 15 million 12 Mg tabs last month to 77 million this month.
The government claimed that between 21 April to 16 May 2021, it distributed 5.37 million Remdesivir vials amongst all states and union territories. Maharashtra received the most, i.e. 1.15 million vials, followed by Karnataka at 575,000 vials and Uttar Pradesh at 495,000. The Centre distributes such medicines based on each state's and union territory's population size and their active Covid caseload.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.